DO letterhead - Departments of Pathology and Laboratory Medicine ...

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 

BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SAN DIEGO SAN FRANCISCO SANTA BARBARA SANTA CRUZ 

Name: Anna B. Berry, MD 

Position: Assistant Professor of Clinical Pathology 

Department of Pathology 

School of Medicine 

Address: Mt. Zion Hospital 

1600 Divisadero St., Room 206, Box 1785 

University of California, San Francisco 

San Francisco, CA 94143-1785 

EDUCATION: 

University of California San Francisco Prepared: 10/06/2009 

CURRICULUM VITAE 

Voice: (415) 353-7650 

FAX: (415) 353-7676 

Email: Anna.Berry@ucsf.edu 

1986-1990 University of Wyoming, Laramie WY B.S. Political Science, 

Chemistry Minor 

1991-1995 University of Nebraska Medical Center, M.D. 

Omaha NE 

1995-1997 Upstate Medical University, Syracuse NY Resident General Surgery 

1997-2000 Upstate Medical University, Syracuse NY Resident Anatomic/Clinical Pathology 

2000-2001 Medical College of Virginia, Richmond VA Resident Anatomic/Clinical Pathology 

2001-2002 Medical College of Virginia, Richmond VA Fellow Molecular Genetic Pathology 

2002-2003 National Cancer Institute, Bethesda MD Fellow Cytopathology 

LICENSES, CERTIFICATION: 

2002 Medical licensure, Virginia (expired) 

2003 Medical licensure, Maryland (expired) 

2005 Medical licensure, California 

2002 Board Certification, Anatomic Pathology and Clinical Pathology 

2003 Board Certification, Cytopathology 

2007 Board Certification, Molecular Genetic Pathology 

PRINCIPAL POSITIONS HELD: 

2003-2005 University of Maryland, Baltimore Assistant Professor Pathology 

2005- now University of California, San Francisco Asst Prof.of Clin.Path Pathology

OTHER POSITIONS HELD CONCURRENTLY: 

2003-2005 University of Maryland, Baltimore Director, Cytopathology 

2003-2005 University of Maryland, Baltimore Director, Cytopathology Fellowship 

2005-2009 University of San Francisco, California Director, Molecular Pathology 

2005-now University of San Francisco, California Director, Molecular Genetic Pathology 

Fellowship (accredited in 2007) 

HONORS AND AWARDS: 

1986-1990 National Merit Special Scholarship 

1986-1990 University of Wyoming Honors and Scholars Program 

1992 Nebraska Medical Association Research Scholarship 

2000 CAP Advocacy School Scholarship 

2002 MCV Institutional Research Grant 

KEYWORDS/AREAS OF INTEREST: 

1 

Anna Berry 

Cancer, cytopathology, fine needle aspiration, molecular diagnostics, DNA, RNA, PCR, RT-PCR, cytogenetics, 

FISH, quality assurance, quality improvement, translational research, apoptosis, public health, legal and regulatory 

issues. 

PROFESSIONAL ACTIVITIES 

CLINICAL 

Director, Molecular Pathology, University of California San Francisco (2005-2009 50% effort): My 

responsibilities as Director included choosing new assays, providing financial justification and planning for new 

assays, hiring, training, and supervising qualified staff members, identifying physical facility requirements and 

equipment requirements, facilitating the acquisition of these items, assuring that appropriate quality control and 

quality assurance procedures are followed, supervising the creation of procedures and policies, planning, 

supervising, and assisting with validation studies, interpreting test results, designing report formats, verifying 

reports, interacting with Clinicians, providing general guidance and advice regarding Clinical Molecular Pathology, 

and interacting with research faculty to facilitate the implementation of appropriate technology and data into patient 

care. During my tenure, we brought up 2 new FISH tests and our first 3 PCR-based tests, with several sequencing 

assays in process. We also moved into a new laboratory space. I provided design requirements and participated in 

all phases of the construction process for the new laboratory. Our laboratory also merged with the sister laboratory 

in the Laboratory Medicine Department and a full-time Director was identified. At this time, I am participating in 

bringing up novel tests that integrate FNA cytology and in supervising the MGP fellow. 

Attending Pathologist, University of California San Francisco (2005- now): I am on service in Cytopathology 

50%. This includes performing and assisting with FNA procedures and interpreting FNA biopsy results, as well as 

interpreting all other types of cytology samples. I am currently training in ultrasound-guided FNA. I am 

responsible for supervising the Immunocyt testing program in this division, which I was instrumental in bringing on 

board. I am also on call for frozen sections about 3-4 days/month. 

Director, Cytopathology Division, University of Maryland Medical System (2003-2005): My duties as Director 

included the daily sign out of all types of cytopathology cases, the performance of fine needle aspiration biopsies 

on demand, compiling statistics and conducting ongoing quality assurance and quality improvement programs, 

facilitating interaction with all outreach services and clinics, assuring compliance with credentialing and 

proficiency standards, appropriate billing practices, and appropriate documentation of services, providing

1997-now, College of American Pathologists 

2000-2002, American Association of Cancer Researchers (Associate) 

2 

Anna Berry 

continuing education programs for staff, and supervising 4 cytotechnologists, 1 cytopathology preparatory 

technician, one part-time secretary, one cytopathology fellow, and residents when on service. During this time 

period, I instituted in house HPV testing and reorganized the Cytopathology Division. 

Presenter, Thoracic Oncology Group Tumor Board, University of Maryland Medical System (2003-2005): My role 

in the Thoracic Oncology Group was to present all patients pathology findings at the weekly working conference 

and to track the patients on the service, providing input as needed regarding their pathology findings. 

Attending, Anatomic Pathology, University of Maryland Medical System (2003-2005): I was on service in 

Anatomic Pathology 85-100%, primarily on the Cytopathology service. I also covered autopsies, some Surgical 

Pathology, and Anatomic Pathology on-call activities (roughly 1 in 7 weeks). 

SUMMARY OF CLINICAL ACTIVITIES (since June 2005, start date at UCSF) 

As the Director of Molecular Pathology at UCSF (which was a 50% time commitment), I evaluated and acquired 

necessary equipment including basic items such as freezers, and more complex equipment such as basic 

thermocyclers, a capillary electrophoresis instrument, and a real-time PCR instrument. I assured that the facility 

met the rigorous standards necessary to do this type of testing, and played the lead role in designing a new, state of 

the art laboratory space. I hired four highly qualified, licensed technologists, and provided training and supervision 

to these technologists. I identified a list of clinically useful assays, assisted with the construction of Return on 

Investment (ROI) analyses to justify the implementation of these assays, actively participated in the validation 

studies for our first PCR-based tests and new FISH tests, supervised the creation of procedures and policies, and 

assured that appropriate quality control and quality assurance procedures were being followed. I participated 

actively in the CAP inspection process, both in preparing for our lab inspection, and in inspecting a large regional 

reference lab (as part of the UCSF team). In addition, I worked with Dr. Joan Etzell (Laboratory Medicine) to 

develop additional ROI analyses for a complete test menu of molecular hematopathology assays, so that we will be 

able to hire additional staff and implement these tests, with an ultimate goal of pursuing outreach clients and 

completing the UCSF Hematopathology service. I also met monthly with all faculty involved with molecular 

testing, under the direction of Dr. Tim Hamill, (Laboratory Medicine) to enhance and coordinate these services and 

to address our common issues. I also supervised Dr. J.P. Grenert and one of our technologists, in providing an 

infrastructure to integrate a clinical translational research mission into the Molecular Pathology clinical laboratory. 

I participated in the merger of our lab with the Laboratory Medicine Molecular Diagnostics laboratory, which was 

successfully carried out. I also actively participated as a member of the search committee to identify a full-time 

director for the Molecular Oncology Division of the new merged lab. In August I turned over most of my 

administrative responsibilities to the new director and will now participate in clinical sign-out, research, and 

development of novel clinical tests, particularly as they relate to the FNA biopsy technique. 

On the Cytopathology service, I perform and interpret FNA biopsies, perform rapid and final interpretations and 

technical assistance for radiology procedures, and interpret Pap tests and non-gynecologic cytology specimens. I 

am currently training to perform ultrasound guided FNA biopsies in the walk-in clinic as well. I also supervise and 

troubleshoot the Immunocyt test, an ancillary test used in the diagnosis of recurrent bladder cancer, which I was 

responsible for validating and implementing in our lab. In addition, I am on call 3-4 days/month for the 

interpretation of frozen sections. I look forward to participating in the ASC Future of Cytopathology Summit, 

which will look at ways to reconfigure the subspecialty in today’s changing pathology environment. I am 

specifically interested in ways to integrate molecular testing into the cytology lab. 

PROFESSIONAL ORGANIZATIONS 

Memberships

2000-now, United States & Canadian Academy of Pathology 

2001-2002, Association for Molecular Pathology (Junior) 

2001-now, American Society of Cytopathology 

2002-now, Papanicolaou Society of Cytopathologists 

2005-now, Association for Molecular Pathology 

2009-current, California Society of Pathology 

2009-current, South Bay Society for Pathologists 

Service to Professional Organizations 

3 

Anna Berry 

2000-2001 CAP Residents’ Forum Executive Committee Delegate to House of Delegates 

2000-2001 CAP General Membership Committee Liaison from RF Executive Committee 

2000-2002 CAP PathPAC Board of Directors Junior Member 

2002 AMP Training and Education Committee Junior Member 

2002-now CAP Spokesperson Program Spokesperson 

2004 PSC Governmental Affairs Task Force Member 

2004-2005 ASC Legislative and Regulatory Affairs Committee Member 

2005-2007 CAP Public Affairs Committee Member 

2006-2008 ASC Laboratory Advisory Committee Member 

2006-2008 CAP Molecular Pathology Resource Committee Member 

2009 CAP Inspection Team Member 

2009 AMA Relative Value Unit Committee Expert Advisor 

2009 ASC Future of Cytopathology Summit Participant 

2009-current Papanicolaou Society Education Committee Member 

2009-current California Delegate to CAP House of Delegates Delegate 

SERVICE TO PROFESSIONAL PUBLICATIONS: 

2005-now Ad hoc referee for Cancer (10 papers in past 5 years) 

INVITED PRESENTATIONS 

INTERNATIONAL 

2005 Breast Simposium, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico 

NATIONAL 

2002 CAP Leadership and Government Affairs Conference, Washington, D.C. (panelist) 

2009 Urine Analysis for Bladder Cancer, University of Colorado, Denver 

REGIONAL AND OTHER INVITED PRESENTATIONS 

1998 Continuing Education Presentation, Community General Hospital, Syracuse, NY 

2000 Continuing Education Presentation, Medical College of Virginia, Department of Pathology 

2002 Grand Rounds, Medical College of Virginia, Department of Pathology 

2003 Maryland Society of Cytology/Metropolitan Washington Area Association of Cytology 

2003 Grand Rounds, University of Maryland Medical System, Department of Gynecology 

2006 An Evidence-Based Approach to Common Problems in Urology, UC San Francisco 

2009 Issues in Urine Cytology, University of Colorado 

2009 Urine Cytology and Ancillary Testing, Current Issues in Pathology (pending for May)

CME COURSES ATTENDED (5 years) 

2004 American Society of Cytopathology Annual Meeting 

2005 American Society of Cytopathology Annual Meeting 

2005 Association for Molecular Pathology Annual Meeting 

2005 Breast Simposium, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico 

2006 An Evidence-Based Approach to Common Problems in Urology, UCSF 

2007 Association for Molecular Pathology Annual Meeting 

2008 United States and Canadian Association of Pathology Annual Meeting 

2009 College of American Pathologists Annual Meeting 

2005-2009 Mechanisms of Disease Conference, UCSF 

UNIVERSITY AND PUBLIC SERVICE 

UNIVERSITY SERVICE 

DEPARTMENTAL SERVICE: (at UCSF, since appointment in June 2005) 

2005-now Molecular Genetic Working Group (with Laboratory Medicine) 

2005-now Hematopathology Fellowship Committee 

2005-now Cytopathology Fellowship Committee 

2007-now Molecular Genetic Pathology Fellowship Committee, Chair 

2008 Pathology Faculty Search Committee 

DEPARTMENTAL SERVICE: (at University of Maryland) 

2003-2005 Division Directors Committee 

2003-2005 Resident Training Committee 

2003-2005 Pathology Information Technology Committee 

2003-2005 Quality Assurance Committee 

2003-2005 AP Director Search Committee 

SUMMARY OF SERVICE ACTIVITIES 

4 

Anna Berry 

My service activities at UCSF has included monthly meetings with the Molecular Genetic Working Group to 

enhance and coordinate molecular diagnostic services and to address common issues with the other section 

leaders. I also participate in committee meetings for the Hematopathology and Cytopathology fellowships, 

which are concerned with fellow selection and evaluation, curriculum planning and evaluation, and ACGME 

compliance. As the fellowship Director, I am the Chair of the committee for the recently accredited 

Molecular Genetic Pathology fellowship. I have also provided input for the departmental website for the 

Cytopathology and Molecular Pathology divisions and am working with several other Pathology faculty 

members to integrate clinical translational research activities into the Molecular Pathology clinical laboratory. 

I also served on a search committee for Molecular Oncology Medical Director in 2008. 

TEACHING and MENTORING

FORMAL SCHEDULED CLASSES FOR UCSF STUDENTS: 

5 

Anna Berry 

Academic Yr Course No. & Title Teaching Contribution 

2005-2006 Medical School, year 1, Metabolism and Nutrition block Laboratory Instructor, 1 laboratory 

2006-2007 Medical School, year 2, Integration and Consolidation block Lecturer; 2 lectures 

2007-2008 Medical School, year 1 Laboratory Instructor, 1 laboratory 



2008-2009 Medical School, year 2 Laboratory Instructor, 2 laboratories 


2009-2010 Medical School, year 2 Laboratory Instructor, 3 laboratories 

FORMAL SCHEDULED CLASSES FOR UMMS STUDENTS: 

Academic Yr. Course No. & Title Teaching Contribution 

2003-2004 Pathophysiology & Therapeutics, MSPR 522 Lecturer, 5 lectures 

POSTGRADUATE AND OTHER COURSES 

2007 An Evidence-Based Approach to Common Problems in Urology, UC San Francisco 

2007-current Cytopathology and Molecular Genetic Pathology lectures for AP residents (6 lectures/yr) 

2008-2009 Didactic, 1:1 teaching for MGP fellow (2 afternoon talks/yr) 

2009 Urine Cytology and Ancillary Testing, Current Issues in Pathology (pending for May) 

POSTDOCTORAL FELLOWS, RESIDENTS, AND FACULTY DIRECTLY SUPERVISED OR 

MENTORED: 

Dates Name Fellow Faculty Role Current Position 

2003-2005 Wei Zhang, MD Pathology Resident Clinical Supervision, Completed Cytopathology 

at UMMS 

mentoring 

Fellowship at University of Penn 

2003-2005 Wenle Wang, MD Pathology Resident Clinical Supervision, Completed GU Pathology 

at UMMS 

mentoring 

fellowship at Johns Hopkins 

2003-2005 Elaine Kling, MD Pathology Resident Clinical Supervision, Completed a Surgical Pathology 

at UMMS 

mentoring 

fellowship at MD Anderson 

2003-2005 Naima Carter- Pathology Resident Clinical Supervision, Completed an informatics 

Monroe, MD at UMMS 

mentoring 

fellowship at Johns Hopkins 

2003-2005 Hong Qi Peng, MD Cytopathology Clinical and Research Assistant Professor at University of 

Fellow 

Supervision, mentoring Maryland 

2005-2006 Kristen Jensen, MD Cytopathology 

Fellow 

Clinical Supervision Assistant Professor, Stanford 

2005-2006 Matthew Greenberg, Cytopathology Clinical Supervision Private Practice 

MD 

Fellow 

2006-2007 Ian Jaffe, MD Cytopathology 

Fellow 

Clinical Supervision Private Practice 

2006-2007 Judy Pang, MD Cytopathology 

Fellow 

Clinical Supervision Faculty at UCSF 

2007-2008 Rebecca Swain, MD Cytopathology 

Fellow 


2007-2008 Annamieke 

Cytopathology Clinical Supervision Faculty at UCSF 

VanZante, MD, PhD Fellow 

2007-2008 James P. Grenert, Informal MGP Clinical Supervision, Faculty at UCSF 

MD, PhD 

Fellow 

Program Director, 

Mentor

2008-2009 Joan Bernard, MD Cytopathology 

Fellow 

2008-2009 Veronia Velasco, Cytopathology 

MD 

Fellow 

2009-2010 Stepahnie McAlhany, Cytopathology 

MD PhD 

Fellow 

2009-2010 Poonam Vohra, MD Cytopathology 

Fellow 

2009-2010 Wendy Yang, MD Molecular Genetic 

Pathology Fellow 

INFORMAL TEACHING: 



Clinical Supervision Cytopathology Fellow 

Clinical Supervision Cytopathology Fellow 

Clinical Supervision, 

Program Director 

2003-now Slide review with clinicians as needed 

2003-now Review of slides on site with clinicians during procedures 

2003-now FNA procedure teaching to residents and fellows 

2005-now Sign out with Fellow and Resident (cytology and molecular) 

2005-now Sign out with molecular technologists 

2005-now Training and mentoring molecular technologists 

2003-2005 Sign out with Resident and Fellow daily 

2003-2005 Slide review with Cytotechnologists as needed 

2003-2005 Review of Hematology slides with attending as needed for correlation 

SUMMARY OF TEACHING HOURS: 

2006-2007: 495 total hours of teaching (including preparation). 

Formal class or course teaching hours (with preparation): 80 hours 

Informal teaching hours: 400 hours 

15 Mentoring hours 

















6 

Molecular Genetic Pathology 

Fellow 

Anna Berry

TEACHING NARRATIVE 

7 

Anna Berry 

My teaching currently is focused on resident and fellow lectures and clinical training for Cytopathology and 

Molecular Genetic Pathology fellows. I give 3 Cytopathology lectures and 3 Molecular Genetic Pathology lectures 

per year, and one slide seminar in Cytopathology as well. In addition, I provide 2 afternoon-long didactic sessions 

during my section rotation for the MGP fellow, as well as coordinating the didactic teaching for the MGP fellow. I 

also am responsible for arranging all rotations for the MGP fellow, and fulfilling all other fellowship director 

responsibilities (15% effort). Additionally, I supervise Cytopathology fellows and residents in the FNA clinic and 

for slide sign-out, about one day per week, and supervise residents and fellows in the molecular laboratory 2 days 

per week. I also provide informal teaching for the molecular staff as needed and for the clinical staff as needed, 

both in relation to molecular cases, and during on-site evaluation of FNA samples for Radiologists and other 

clinicians. In addition, I provide formal and informal teaching and supervision for a molecular technologist as part 

of our formal training program. I assist with the medical student laboratories as needed (6 labs this academic year). 

I will be teaching a course at the UCSF GME Course Current Issues in Pathology and have applied to teach a 

course at the USCAP meeting in 2011. 

RESEARCH AND CREATIVE ACTIVITIES 

PEER REVIEWED PUBLICATIONS: 

1. Peng HQ, Greenwald BD, Tavora FR, Kling E, Darwin P, Rodgers WH, Berry A. Evaluation of performance of 

EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas, Diagn Cytopathol. 

2008 May; 36(5): 290-6. 

2. Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts 

recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy, BJU Int. 2009 

Feb 10. [Epub ahead of print] 

NON-PEER REVIEWED PUBLICATIONS: 

Review Articles 

1. Greene KL, Berry A, Konety BR. Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer, Rev Urol. 

2006 Fall;8(4): 190-7. 

Books and Chapters 

1. O’Grady, A.B., Atkins, K.A., and Powers, C.N.: Fine Needle Aspiration Biopsy of Endocrine Glands, In: Lloyd, 

R.V. (Ed). Endocrine Pathology: Differential Diagnosis and Treatment. City: Humana Press, October 2003. 

RESEARCH PROGRAM 

I am interested primarily in translational research. In general, I am interested in investigating and promoting the 

use of molecular testing to diagnose and describe solid tumor specimens in the clinical laboratory, to provide 

information that is relevant to patient care. To that aim I will continue to participate in the expansion of the 

Molecular Diagnostics laboratory. Specifically, I will continue to validate and add tests based primarily on data 

that currently exists in the medical literature, with the aim of applying these tests to small tissue specimens such as

8 

Anna Berry 

fine needle aspiration material, to improve the efficiency, detail, and accuracy of cancer diagnosis using these 

specimen types, limiting the time to diagnosis and improving patient care. To this aim, I have worked with several 

other Pathology faculty members to integrate Departmental molecular research projects into our clinical laboratory 

structure. During my tenure as laboratory director, we employed one technologist who was dedicated primarily to 

translational research, and one faculty member, who I supervise, to assist her in carrying out faculty projects. This 

program continues and will facilitate my future work. 

I am currently planning to participate in at least one project with Dr. Adil Daud in Clinical Oncology. Dr. Daud 

published a paper in the Journal of Clinical Oncology showing a good response to IL-12 plasmid electroporation 

therapy in melanoma patients. We are planning to integrate FNA biopsy testing as the best method for clinical 

follow-up in these patients during the Phase II trial and have submitted a proposal for an R-01 grant for this 

purpose. We are also working on a separate proposal integrating FNA techniques into the delivery of therapy, as 

well as into the monitoring phase. I have a clinical background in melanoma testing, as I completed my cytology 

fellowship training at the National Cancer Institute, which has a large clinical research program in melanoma. I 

would like to combine these experiences to move forward and collaborate with Dr. Daud more extensively on 

future melanoma-related research projects. 

In addition, I am participating in some ongoing projects related to Immunocyt and Urovysion testing, both of which 

were validated and instituted under my direction in January of 2007. I have been collaborating in a study 

evaluating the cost-effectiveness of reflex Immunocyt testing with Dr. Badrinath Konety, which arose from an 

abstract we presented at the AUA meeting this year. We are examining our data from 2007 and using 

epidemiologic analysis methods to estimate the cost savings associated with performing the Immunocyt test on all 

cytologically atypical urine samples. Immunocyt is not widely available at this time, and there are no published 

guidelines for the use of this test, so this information should be timely and clinically valuable. I am also separately 

analyzing our diagnostic data in relation to the reflex Immunocyt testing, looking for ways to improve our 

morphologic analysis, and again attempting to determine the best utilization practices for this test. I expect both of 

these publications to be complete before the end of the academic year. 

I have also been collaborating with Dr. Konety in an ongoing project to assess the value of Urovysion testing in 

urine specimens obtained from bladder reconstructions. These samples have characteristics that make them 

suboptimal for this type of analysis, and many are insufficient. While we continue to accept them for analysis, it 

seems likely that this is not an efficient use of resources. We are attempting to determine the best use of this test in 

this circumstance. I am also collaborating with Dr. Peter Carroll regarding this issue to evaluate the efficacy of 

using a special catheter to evaluate only the urethra for recurrence, providing a more appropriate sample for 

analysis. This project also arose from an abstract we presented at the AUA meeting. I am separately looking at 

issues related to Urovysion utilization, including frequency of testing for bladder cancer follow-up. Urovysion is a 

useful but very expensive test that is widely available. Clear guidelines for the use of this test would reduce health 

care costs and improve patient care. 

I am also in the process of creating innovative and targeted evaluation techniques for the MGP fellowship, which 

will be more specifically applicable to the practice of Molecular Genetic Pathology. I hope to publish the results of 

this effort at some point in the future. 

Finally, I am writing two chapters for a Spanish-language comprehensive book on breast cancer, one on breast 

cancer pathology and one on molecular techniques in breast cancer. This endeavor arose from a meeting that I 

spoke at in 2005 at the Universidad Autonoma de Nuevo Leon in Monterrey, Mexico at the invitation of Servando 

Cardona, a breast surgeon at that institution who is attempting to change the way breast cancer is treated in Mexico. 

He has created one of the first comprehensive breast care centers in his country and is pushing to bring current 

technology and practices to the forefront there.

DO letterhead - Departments of Pathology and Laboratory Medicine ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?